


PRODUCT INFORMATION



UAMC-3203 (hydrochloride)

Item No. 29346

CAS Registry No.: 2271358-65-5
Formal Name: 4-(cyclohexylamino)-3-[[phenylmethyl]amino]-N-[2-(1-piperazinyl)ethyl]-benzenesulfonamide, monohydrochloride
MF: $C_{25}H_{37}N_5O_2S \cdot HCl$
FW: 508.1
Purity: $\geq 98\%$
UV/Vis.: λ_{max} : 236, 286 nm
Supplied as: A crystalline solid
Storage: $-20^{\circ}C$
Stability: ≥ 2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

UAMC-3203 (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the UAMC-3203 (hydrochloride) in the solvent of choice, which should be purged with an inert gas. UAMC-3203 (hydrochloride) is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of UAMC-3203 (hydrochloride) in these solvents is approximately 25 and 10 mg/ml, respectively.

UAMC-3203 (hydrochloride) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, UAMC-3203 (hydrochloride) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. UAMC-3203 (hydrochloride) has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

UAMC-3203 is an inhibitor of ferroptosis that has an IC_{50} value of 10 nM for inhibition of erastin-induced ferroptosis in IMR-32 neuroblastoma cells.¹ It decreases iron-induced plasma lactate dehydrogenase (LDH) levels in a mouse model of acute iron poisoning when administered at a dose of 20 μ mol/kg. It is not toxic to mice following chronic administration of a 20 μ mol/kg dose for four weeks. UAMC-3203 has increased solubility and a longer half-life in mouse, rat, and human microsomes and isolated plasma than the ferroptosis inhibitor ferrostatin-1 (Item No. 17729). In an *in silico* membrane dynamics study, UAMC-3203 was incorporated into a phospholipid bilayer.

Reference

1. Devisscher, L., Van Coillie, S., Hofmans, S., *et al.* Discovery of novel, drug-like ferroptosis inhibitors with in vivo efficacy. *J. Med. Chem.* **61**(22), 10126-10140 (2018).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/22/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM